Drug Trial Radar · NCT03374085
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
200
Actual
Start
Feb 6, 2018
Primary completion
Aug 20, 2025
Study completion Oct 23, 2025
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Dec 15, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM). All eligible subjects must be previously treated with at least 3 prior regimens including lenalidomide, pomalidomide, a proteasome inhibitor and an anti-CD38 antibody and be refractory to their last line of therapy.
Conditions
- Multiple Myeloma
Interventions
CC-92480Drug
CC-92480
DexamethasoneDrug
Dexamethasone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs)Time frame: From enrollment until at least 28 days after completion of study treatment
- Pharmacokinetics- AUCTime frame: Up to approximately 28 days
- Pharmacokinetics- CmaxTime frame: Up to approximately 28 days
- Pharmacokinetics- TmaxTime frame: Up to approximately 28 days
- Pharmacokinetics- t1/2Time frame: Up to approximately 28 days
- Pharmacokinetics- CL/FTime frame: Up to approximately 28 days
- Pharmacokinetics- Vz/FTime frame: Up to approximately 28 days
- Maximum tolerated dose (MTD)Time frame: Up to approximately 28 days
- Overall Response Rate (ORR)Time frame: Up to approximately 3 years
Locations
54 sites in 11 countries. Site status is shown where the registry gives one.
Local Institution - 103
Duarte, California
Local Institution - 102
Atlanta, Georgia
Local Institution - 105
Boston, Massachusetts
Local Institution - 111
Buffalo, New York
Local Institution - 104
New York, New York
Local Institution - 108
Spartanburg, South Carolina
Local Institution - 101
Nashville, Tennessee
Local Institution - 106
Houston, Texas
Local Institution - 112
Charlottesville, Virginia
Local Institution - 109
Seattle, Washington
Local Institution - 806
Fitzroy, Australia
Local Institution - 804
Camperdown, New South Wales, Australia
Local Institution - 802
Adelaide, South Australia, Australia
Local Institution - 805
Clayton, Victoria, Australia
Local Institution - 803
Melbourne, Victoria, Australia
Local Institution - 904
Antwerp, Belgium
Local Institution - 905
Ghent, Belgium
Local Institution - 901
Leuven, Belgium
Local Institution - 902
Yvoir, Belgium
Local Institution - 201
Calgary, Alberta, Canada
Local Institution - 204
London, Ontario, Canada
Local Institution - 205
Ottawa, Ontario, Canada
Local Institution - 202
Toronto, Ontario, Canada
Local Institution - 206
Montreal, Quebec, Canada
Local Institution - 203
Québec, Quebec, Canada
Local Institution - 503
Aarhus N, Denmark
Local Institution - 501
Copenhagen, Denmark
Local Institution - 502
Odense, Denmark
Local Institution - 601
Helsinki, Finland
Local Institution - 001
Athens, Greece
Local Institution - 705
Chuo-ku,chiba, Japan
Local Institution - 703
Fukuoka, Japan
Local Institution - 704
Kashiwa, Japan
Local Institution - 702
Kobe, Japan
Local Institution - 706
Kyoto, Japan
Local Institution - 701
Okayama, Japan
Local Institution - 152
Seoul, South Korea
Local Institution - 150
Seoul, South Korea
Local Institution - 151
Seoul, South Korea
Local Institution - 403
Badalona (Barcelona), Spain
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.